MoonLake Immunotherapeutics
Support and Resistance Levels
Past performance
News About MLTX
All events for MLTX
All deals for MLTX
Financial Ratios
Financial Statements
MLTX vs Sector & Peers
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland. Website moonlaketx.com
Headquarters Zug, ZG, CH